EXPERIMENTAL THERAPY OF CHRONIC COLITIS IN RHESUS MACAQUES

恒河猴慢性结肠炎的实验治疗

• 批准号: 6116670
• 负责人: NICHOLAS WILLIAM LERCHE
• 金额: $ 8.99万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-01 至 2000-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6116670
• 关键词: Mammalia; intestines; pharmacology

Significance Chronic colitis and diarrhea is a well recognized syndrome in a small proportion of rhesus macaques maintained in captivity. The etiology and pathogenesis of this syndrome is not well understood, although artificial weaning of young macaques has been identified as a risk factor for development of chronic colitis in epidemiologic studies. As currently defined, this syndrome is includes persistence of diarrhea and colitis in the absence of any identifiable enteric pathogen. Objectives This spontaneously occurring disease is being evaluated as a model of inflammatory bowel disease (IBD) in humans, and for testing of novel therapeutic compounds for the treatment of IBD. Results Several novel compounds have been evaluated for efficacy in the treatment of chronic colitis in the rhesus model. One compound, GW-83X has shown potential as a therapeutic agent, achieving clinical improvement in treated animals. Future Directions Additional compounds which are analogues of GW-83X will be evaluated at various dose levels using this macaque model system. KEY WORDS rhesus macaque, colitis, therapy FUNDING Glaxo-Wellcome

意义慢性结肠炎和腹泻是公认的 一小部分恒河猴的综合症维持在 被囚禁。本病的病因病机尚不清楚。 理解，尽管人工断奶幼年猕猴已经 被确认为慢性结肠炎发生的危险因素 流行病学研究。按照目前的定义，这种综合症是 包括持续腹泻和结肠炎在没有任何 可识别的肠道病原体。这是自发的目标 正在对正在发生的疾病作为炎症性肠病的模型进行评估 人类疾病(IBD)，并测试新的治疗方法 治疗IBD的化合物。结果合成了几个新化合物 对慢性结肠炎的治疗效果进行了评估 在恒河猴模型中。一种化合物GW-83X已显示出作为一种 治疗剂，在治疗动物中实现临床改善。 GW-83X类似物的未来发展方向 将在不同的剂量水平下使用这个猕猴模型进行评估 系统。关键词恒河猴、结肠炎、治疗资金 葛兰素史克-惠康